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Abstract
Carcinogenesis is a complex process with multiple genetic and environmental factors contributing to the development of
one or more tumors. Understanding the underlying mechanism of this process and identifying related markers to assess the
outcome of this process would lead to more directed treatment and thus significantly reduce the mortality rate of cancers.
Recently, molecular diagnostics and prognostics based on the identification of patterns within gene expression profiles in
the context of protein interaction networks were reported. However, the predictive performances of these approaches were
limited. In this study we propose a novel integrated approach, named CAERUS, for the identification of gene signatures to
predict cancer outcomes based on the domain interaction network in human proteome. We first developed a model to
score each protein by quantifying the domain connections to its interacting partners and the somatic mutations present in
the domain. We then defined proteins as gene signatures if their scores were above a preset threshold. Next, for each gene
signature, we quantified the correlation of the expression levels between this gene signature and its neighboring proteins.
The results of the quantification in each patient were then used to predict cancer outcome by a modified naı ¨ve Bayes
classifier. In this study we achieved a favorable accuracy of 88.3%, sensitivity of 87.2%, and specificity of 88.9% on a set of
well-documented gene expression profiles of 253 consecutive breast cancer patients with different outcomes. We also
compiled a list of cancer-associated gene signatures and domains, which provided testable hypotheses for further
experimental investigation. Our approach proved successful on different independent breast cancer data sets as well as an
ovarian cancer data set. This study constitutes the first predictive method to classify cancer outcomes based on the
relationship between the domain organization and protein network.
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Introduction
Cancer development is a complex process driven by multiple
genetic and environmental factors [1,2,3]. Understanding the
underlying mechanism of this process and identifying related
markers to assess the outcome of this process could lead to better
management and treatment of this complex disease. For example,
the majority of breast cancer patients are currently over-treated
[4] due to the lack of accurate assessment of the risk of metastasis.
As a result, a substantial proportion of patients are receiving the
otherwise avoidable aggressive adjuvant therapy in accordance to
the current guidelines [5]. Although the importance of identifying
prognostic signatures that could accurately predict cancer
outcomes is widely appreciated, it has remained a challenging
task. With the emergence of large amounts of DNA microarray-
based tumor gene expression profiles, molecular diagnostics and
prognostics have begun to provide solutions to this challenge [6].
Several predictive tools [7,8,9,10] were reported to classify
different cancer outcomes primarily based on the identification
of gene expression signatures observed in these outcomes.
However, the predictive performance of these approaches was
limited. For instance, in two large-scale expression studies [9,10],
approximately 70 gene markers were identified that could be used
in the prediction of the metastasis in breast cancer, but only with
an accuracy of 60–70%. This relatively low accuracy could be
explained by some intrinsic shortcomings of the microarray data,
as different experiment and analysis designs could yield inconsis-
tent results due to systematic errors [11] and by the heterogeneity
of carcinogenesis resulting from multiple factors such as specific
samples and cancer types [6]. Recently, the prognostic predictive
performance has been improved by integrating the gene
expression profiles and the human interactome data, based on
the notion that disruption of protein interaction network might
affect disease outcomes [12]. Protein-protein interactions (PPIs)
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molecular level, any genetic alternation such as somatic
mutations, translocations, deletions and insertions that modify
expressed protein-coding genes could cause changes in a PPI-
based regulatory mechanism that governs normal cell function.
This could lead to aberrant or uncontrolled cell growth and
eventually to cancer [1]. For example, mutations in the zinc
finger domain presented in the oncoprotein MDM2 can disrupt
the interaction of MDM2 with ribosomal proteins L5 and L11
and mediate p53 degradation [13]. The recent availability of
large-scale PPI networks has made it possible to identify better
gene signatures by combining the gene expression measurements
with the perturbed protein interaction networks in the cell.
Chuang and colleagues [14] developed a method to find
subnetwork-based signatures by incorporating PPI networks
and gene expression profiles. The resultant subnetworks with
their gene expression profiles were used as markers to predict the
prognosis of breast cancer patients. This study yielded an
accuracy of 70–72% in determining a breast cancer as metastatic
versus non-metastatic. Their study revealed the usefulness of the
PPI network in conjunction with the gene expression profiles
and provided a starting point to future studies. More recently,
Taylor and colleagues [12] proposed a new methodology to
predict breast cancer outcome based on the correlation of gene
expression profiles between hub proteins and their interacting
partners in the PPI network. This approach showed improved
predictive performance at an accuracy of 76% when tested on a
different set of gene expression profiles from breast cancer
patients. These studies demonstrated that the topology of a PPI
network could be a helpful line of biological evidence in
differentiating cancer outcomes. In the meantime, however,
there are other important biological elements that might be
involved in the development of cancer genome and phenotype.
To further strengthen the power of novel predictive tools, these
lines of biological evidence need to be investigated and incor-
porated if proven useful.
In an alternative approach, we focused on the prediction of
cancer outcomes within the context of domain interaction
network. Domains are defined as independent structure and/or
functional blocks of proteins. It is clear that protein-protein
interactions are mediated by the interactions between protein
domains [15]. For example, SH2 domains mediate many critical
protein interactions in signal transduction [16,17]. Disrupted
domain-domain interactions (DDIs) have been shown to stop the
chain reaction of biological pathways at any point [18,19], thus
lead to various diseases [20,21,22]. This fact has motivated us to
investigate the disruptions in a PPI network that are caused by
DDIs, which might be a defining feature of tumor phenotype
and thus could be used to determine patient prognosis. In the
context of DDIs, we can categorize a given interacting protein
into one of the two types based on the relationship of this
protein and its neighboring proteins in the protein interaction
network (Figure 1). We call a protein a ‘singlish-interface’
protein if it interacts with its neighboring proteins through the
same domain-domain interaction; therefore, those domain-
domain interactions are mutually exclusive (Figure 1A). Con-
versely, we call this protein a ‘multiple-interface’ protein if it
interacts with its neighboring proteins through different domain-
domain interactions, as those interactions are simultaneously
possible (Figure 1B). It has been demonstrated that singlish-
interface proteins evolve faster than multiple-interface proteins
and are more likely to interrupt protein interactions and disturb
the protein interaction network [23]. Therefore, we hypothesize
that singlish-interface proteins are also more likely to be involved
Author Summary
It is widely known that cancer is a complex process in
which a large number of genes appear to be involved.
Through experimental approaches, some oncogenes and
tumor suppressors have been identified as playing
important roles in the signaling and the regulatory
pathways. However, we have not fully understood the
complete mechanism of how cancer develops and how it
leads to different disease outcomes (aggressive/dangerous
or non-aggressive/less-dangerous). In order to identify a
list of gene signatures and better predict cancer outcome,
we developed an integrated and systematical approach by
investigating gene expression profiling alternation caused
by disruptions between protein-protein interactions and
domain-domain interactions in the human interactome.
Our approach achieves the favorable predictive perfor-
mance if tested on a set of well-documented breast cancer
patients, which suggests that the disrupted interactome is
important to determine patient prognosis. Our approach is
robust if tested on other independent data sets. This work
provides a promising prognostic tool to classify different
cancer outcomes.
Figure 1. A schematic view of a ‘singlish-interface’ protein and a ‘multiple-interface’ protein. Given a protein (red node) and its
neighboring proteins in the protein interaction network, we can define it as a ‘singlish-interface’ protein or a ‘multiple-interface’ protein. The ‘singlish-
interface’ protein interacts with its neighboring proteins through the same domain (the yellow line); therefore, those domain-domain interactions are
mutually exclusive. Conversely, the ‘multiple-interface’ protein interacts with its neighboring proteins through different domains (blue lines), as those
interactions are simultaneously possible.
doi:10.1371/journal.pcbi.1001114.g001
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proteins. Meanwhile, DDIs could be interrupted by genomic
variations located within interacting domains. One type of these
genomic variations is somatic mutation. Somatic mutations are
genetic alternations in DNA that are neither inherited nor
passed to offspring. Some of these are thought to be driving the
cancer process and have been refereed to as ‘‘driver mutations’’,
which can contribute to the development of the cancers or other
diseases [24]. Therefore, we sought to investigate the perturba-
tion of the protein interaction network in cancerous cells caused
by the presence of somatic mutations, and to examine whether
somatic mutation data could provide help in the prediction of
cancer outcome. In summary, in addition to PPI data and gene
expression data, we looked into incorporating two other types of
data that might be functionally associated to the disturbance of
the PPI networks: domain-domain interactions (DDIs) and
somatic mutations.
In this study, we propose an integrated approach, named
CAERUS, to predict the likelihood of cancer outcomes in
unknown cancer patients provided the gene expression profiles
of these patients are available. To implement CAERUS, we first
developed a model to score each protein present in the
expression profiles based on the domain connections to their
interacting partners and the somatic mutations located in the
domains. Next, gene signatures defined as proteins whose scores
are above a preset threshold were identified. Then we computed
the correlation of gene expression profiles of the gene signatures
and their neighboring proteins. A modified naı ¨ve Bayes classifier
was used to predict cancer outcome based on this correlation.
Compared to previous studies, our study has several advantages.
First, apart from the PPI network and the gene expression
profiles, the DDI network and the somatic mutations within
domains were integrated into our predictive model, which has
improved the prediction performance to an accuracy of 88.3%,
sensitivity of 87.2% and specificity of 88.9%. Second, our results
compiled a list of cancer-associated gene signatures and
domains, which provided testable hypotheses for further
experimental investigation. Third, our approach is not specific
to a specific cancer dataset and can thus be applied to different
independent cancer data sets.
Results
Parameter tuning and validation on breast cancer data
We tested whether our identified gene signatures are good
indicators to differentiate a set of two groups of sporadic and non-
familial breast cancer patients [25]. We defined patients who were
disease free after extended follow-up as patients with ‘good
outcome’ and those who died of disease as patients with ‘poor
outcome’. The patient data was filtered to remove patients that
were still alive with disease or dead from other reasons, as reported
by Taylor [12]. The resultant dataset contained 179 patients with
‘good outcome’ and 74 patients with ‘poor outcome’. For each
patient, a profile was computed based on the difference of the gene
expression value between the gene signatures and their neighbor-
ing proteins. For the identification of gene signatures, we applied a
scoring procedure to the protein domains present in each gene
products based on the number of mutually exclusive DDIs they
participated in (see methods). Using this approach we found that
only one parameter needed to be tuned: the threshold (c)o f
domain index scores (Sd). The threshold (c) was tuned by testing
our approach on the breast cancer data set using different Sd values
(see methods). We then evaluated the performance of our
approach by calculating three performance measurements:
accuracy, sensitivity and specificity. In this study, accura-
cy=(TP+TN)/(TP+FP+TN+FN); sensitivity=TP/(TP+FN); spe-
cificity=TN/(TN+FP). A true positive is defined as the case that a
‘‘poor outcome’’ patient was successfully predicted as having the
‘‘poor outcome’’ and a true negative is defined as the case a ‘‘good
outcome’’ patient was correctly predicted as having the ‘‘good
outcome’’. From the observation of the performance plot based on
different Sd (Figure 2), we concluded that our approach achieved
the best performance with the accuracy of 85.8%, the sensitivity of
87.1% and the specificity of 82.6% when the threshold (c)o f
domain index scores (Sd) were set as 50. We also found that with
higher threshold (c), a smaller set of gene signatures were
generated, and consequently lower the performance was. On the
contrary, with lower threshold (c), the gene signature list contained
higher noise and generated more false positives and negatives.
Next, we did survival analysis to prove the ability to predict
survival of our approach under this setting and observed the
significantly different 10-year survival (Mantel-Cox Log Rank test,
nominal P-value=2.19610
28) (Figure 3) between two groups of
patients.
The identified biomarkers might be involved in
carcinogenesis
A total of 171 gene signatures were identified in a breast cancer
data set [25] using our approach at the threshold (c)o f5 0a s
described in the above section. These gene signatures mainly are
involved in 5 major cancer-related biological processes: transcrip-
tion (P-value=9.3610
210), DNA repair (P-value=3.8610
25),
signal transduction (P-value=7.9610
213), cell cycle (P-val-
ue=1.1610
29) and protein phosphorylation (P-val-
ue=2.9610
226) if we performed GO Term enrichment analysis
using FuncAssociate [26] (Figure 4A). The complete list of over-
represented GO terms associated with identified gene signatures is
in the supplementary materials (Table S1). In addition, 36 human
biological pathways can be derived when we mapped the gene
signatures to the Reactome database that contains manually
curated human biological pathways [27] (P-value,0.001)
(Figure 4B). For instance, the well-known oncogenic transcription
factors such as FOS, JUN and NFkB were identified as gene
signatures by this study. We also identified some DNA repair genes
including XRCC5, MSH, PCNA and others as gene signatures.
These genes were demonstrated to cause cancer because
mutations in those genes disable the ability of DNA repairing,
which subsequently leads to the accumulation of mutations
[28,29,30]. Genes involved in signal transduction, an important
type of pathways in cancer development, such as MARK14,
VAV1 and PIK3R1 were also identified as gene signatures in this
study. Besides, a group of cyclin-dependent kinases (CDK2,
CDK3, CDK4, CDK6) that control cell proliferation [31] and
genes (SRC, ABL1) related to protein phosphorylation [32] were
also identified by our approach. In summary, there were 38% (65
out of 171) of the identified gene signatures found to be the genes
associated with cancers in Online Mendelian Inheritance in Man
(OMIM; http://www.ncbi.nlm.nih.gov/omim/). This percentage
is significantly greater than what could be found purely by chance
(Adjusted P-value,10
212, by Fisher’s Exact Test), indicating the
capability of our approach to identify disease genes. Interestingly,
only 15% (26 out of 171) of the identified gene signatures were
known cancer susceptibility genes compared to a list of 410 genes
downloaded from The Cancer Gene Census (http://www.sanger.
ac.uk/genetics/CGP/Census/), whose mutations had been caus-
ally implicated in cancer, but the small overlap is still statistically
significant at P-value of 7.7610
26 by Wilcoxon Test. This result
was consistent with those of the previous studies, which yielded
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importance that the cancer susceptibility genes contribute to
cancer prognosis, we employed these 410 known cancer
susceptibility genes as signature genes to predict breast cancer
outcomes, we observed a relatively low accuracy of 72.6%,
sensitivity of 72.9% and specificity of 71.4% if tested on the same
breast cancer set (Figure S1). Taken together, the low percentage
of known cancer susceptibility genes present in our gene signature
list suggests that the mutations in not only these genes, but also
other genes, might collectively affect the process of tumor-
aggressiveness and response to therapy in various ways by
disrupting the modularity of the PPI network. Among other genes
in our gene signature list but not in the list of known cancer
susceptibility genes, 32% (46 out of 145) of genes can be mapped
to the human biological pathways in which known cancer
susceptibility genes anticipate in the Reactome database (P-
value=2.1610
28 by Z-test). Therefore, we speculated that the
other genes could be the downstream effectors of the cancer
susceptibility genes and the changes in their expression value could
reflect the disruption of the PPI network caused by the mutations
in the cancer susceptibility genes. In order to investigate what
types of domains tend to exist in ‘singlish-interface’ proteins and
disrupt protein interactions, we calculated the number of involved
domain-domain interactions of each domain in ‘singlish-interface’
proteins against the whole genome and compared it to that
expected by chance (P,0.01, Z-test) (see Figure 1). We identified a
list of 29 over-represented domains within 171 gene signatures
(Table 1). Interestingly, 93% (27 out of 29) of the domains were
annotated as cell signaling domains such as SH2, Pkinase and Ras
according to the SMART database [33] indicating that these
domains were likely to play a critical role in carcinogenesis
through disrupting the protein interactions within signaling
pathways. For example, the SH2 domain of the oncoprotein Src
interacts with 86 domains within 57 proteins. It has been
demonstrated that SH2 domain regulates intracellular signalling
cascades by interacting with high affinity to phosphotyrosine-
Figure 2. The performance of our approach using different thresholds of domain index scores (Sd). Curve of receiver operating
characteristics (ROC) plotted for different thresholds when our approach was tested against the breast cancer data set incorporating somatic
mutation data and without incorporating somatic mutation data. The area under the curve (AUC) plotted for without somatic mutations and with
somatic mutations is 0.854 and 0.892, respectively.
doi:10.1371/journal.pcbi.1001114.g002
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migration and proliferation [36]. Another example is that the
Pkinase domain contains the catalytic function of protein kinases
that are essential in the process of phosphorylation [37,38]. Many
diseases including cancer are caused by dysfunction of phosphor-
ylation [39].
Knowing which somatic mutations are present increases
the accuracy of our approach
It is widely accepted that genetic changes such as somatic
mutations are implicated in cancer development [40]. Also, some
somatic mutations reveal the role of functional domains in
hereditary disorders and complex diseases [41]. For example,
tumors highly sensitive to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors often contain dominant
mutations in exons that encode a portion of the tyrosine kinase
(TK) domain of EGFR [42]. To investigate the possibility that
somatic mutations within domains represent another type of
important signal to differentiate two classes of patients, we
incorporated the somatic mutation data compiled from the
COSMIC database to our scoring model (see methods) by
searching for the genes having mutually exclusive domains that
harbor somatic mutations. We hypothesized that these mutations
could disrupt DDIs and PPIs and consequently change the
modularity of the human protein interaction network. By
employing the modified domain index function that incorporates
the somatic mutation data, we tuned again the threshold (c) using
different Sd values. At the threshold of Sd=80, our approach
identified 126 gene signatures and achieved the accuracy of
88.3%, the sensitivity of 87.2% and the specificity of 88.9% when
tested on the breast cancer outcome data (Figure 2). All of 126
gene signatures belong to a list of 171 gene signatures identified by
the CAERUS approach without integrating the somatic mutation
data, which indicates that 45 gene signatures failed to pass a preset
threshold after the somatic mutation data were used. To test
weather the slight improvement on predictive performance (0.038
difference in the area under the ROC curve) is statistically
significant, we tested CAERUS on randomized 126 genes from
the list of 171 gene signatures and repeated this procedure 100
times (Figure S2). We found that this improvement is indeed
statistically significant at the P-value of 2.8610
25 by Wilcoxon
Test. Compared to the performance of CAERUS’ that does not
incorporate the somatic mutation data, the improvement on
CAERUS’ performance by integrating the somatic mutation data
suggests that the somatic mutation data can be used to supplement
our accuracy to predict cancer survival outcome. However, the
capability of using the mutation data appears limited due to the
fact that not all mutations are driving the development of the
cancer, the so-called ‘‘driver mutations’’ [43]. Minor performance
improvement could be explained by the incompleteness of
currently available somatic mutation data or the bias introduced
by ‘‘passenger mutations’’. With the help of the numerous Cancer
Genome Projects [44,45], the size of the somatic mutations data in
human will grow in the near-future possibly providing us with even
better indications from mutation data.
Using gene expression, and the comparison with other
approaches
Identifying novel prognostic markers to classify different cancer
outcomes has been widely studied with the increasingly available
gene expression profiles. The approaches described in previous
publications can be categorized into three classes: 1) gene
expression pattern-based method, in which markers are selected
based on whether their expression profiles can differentiate
different groups of patients [9,10]; 2) PPI subnetwork-based
method, in which each marker represented as a subnetwork in the
PPI network was identified by maximizing the mutual information
measuring the association between the expression value of each
Figure 3. The ability of our approach to predict survival between two groups of breast cancer patients. The Kaplan-Meier survival plot
for disease-free survival are shown for two group (‘‘Good outcome’’ vs. ‘‘Poor outcome’’) of breast cancer patients. The difference between two
groups is statistically significant for 10-year survival at the P-value of 2.19610
28 by the Mantel-Cox Log Rank test.
doi:10.1371/journal.pcbi.1001114.g003
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PLoS Computational Biology | www.ploscompbiol.org 5 March 2011 | Volume 7 | Issue 3 | e1001114Figure 4. The biological functions of identified biomarkers. (A) Thebiologicalnetworkof171genesignaturesidentifiedinthebreastcancerdata
set using our approach. Each gene is labeled as different colors based on it biological function annotation derived from its gene ontology terms. (B) The
pathway organization of identified gene signatures involved in 36 human biological pathways when they were mapped to the Reactome database [27].
doi:10.1371/journal.pcbi.1001114.g004
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modularity-based method in which each gene signature was
identified by comparing the difference of the gene expression value
between a hub gene and their interacting partners in the PPI
network [12]. In this study, we employed a novel approach based
on finding genes in the PPI network with mutually exclusive
domains and somatic mutations located in these domains as the
markers. Wang et al [10] and van de Vijver et al [25] reported
63% and 62% accuracy, respectively, for the prediction of
metastasis using gene expression pattern-based methods. Using
the PPI subnetwork-based method, Chuang et al [14] yielded the
accuracy of 72.2% and 70.1% using the same data set as Wang et
al and van de Vijver et al did. Using the PPI modularity-based
method, Taylor et al [12] reported the accuracy of 76% tested on
the breast cancer patient data set. We first applied our approach
on the same data set as Chuang et al [14] used and adopted the
identical training and testing strategy (five-fold cross-validation)
and observed that our approach achieved the accuracy of 83.2%,
the sensitivity of 84.6% and the specificity of 82.5%. Next, we
applied our approach on the same data set as Taylor et al [12]
used and adopted the identical training and testing strategy (five-
fold cross-validation) and observed that our approach achieved the
accuracy of 87.3%, the sensitivity of 87.2% and the specificity of
88%, which indicates that our method outperforms other
approaches and provides a promising solution to predict cancer
outcome (Figure 5).
The robustness of our approach
To test the robustness of our approach on different
independent data sets or different types of cancer, we first
applied our approach to a data set that included 236 primary
invasive breast tumors [46]. Using five-fold cross-validation, our
approach achieved the accuracy of 92.4%, the sensitivity of 94%
and the specificity of 90.2%. Our approach also revealed
significantly different 10-year survival (Mantel-Cox Log Rank
test, nominal P-value=1.8610
225) (Figure 6A). Another inde-
pendent data set that includes 117 primary breast tumors was
utilized to evaluate the performance of our approach [47]. Using
the leave-one-out cross-validation (LOOCV) strategy due to
insufficient sample size, our approach achieved the accuracy of
89.8%, the sensitivity of 85.7% and the specificity of 91.6% with
the significantly different 10-year survival (Mantel-Cox Log Rank
test, nominal P-value=7610
24) (Figure 6B). These results
indicate that our predictive approach has good performance in
predicting breast cancer outcome when tested on different
independent data sets. Next, we compiled a set of 110 patients
Table 1. A list of over-represented domains within gene
signatures.
Domain Name DDIs P-value
PF00017 SH2 86 1.63E-24
PF00018 SH3_1 70 1.39E-23
PF00069 Pkinase 49 1.41E-23
PF00071 Ras 45 2.13E-23
PF00170 bZIP_1 42 2.49E-23
PF07716 bZIP_2 34 2.97E-23
PF00130 C1_1 23 5.56E-23
PF00271 Helicase_C 23 6.34E-23
PF00270 DEAD 23 7.18E-23
PF00169 PH 22 7.21E-23
PF00096 zf-C2H2 22 9.03E-23
PF05739 SNARE 21 9.94E-23
PF00023 Ank 20 9.98E-23
PF01833 TIG 20 1.44E-22
PF00433 Pkinase_C 19 2.17E-22
PF00004 AAA 18 9.83E-22
PF01423 LSM 17 1.04E-21
PF00786 PBD 16 3.90E-21
PF00134 Cyclin_N 14 4.60E-17
PF00022 Actin 14 9.84E-17
PF00804 Syntaxin 13 1.80E-16
PF00595 PDZ 12 2.96E-15
PF00125 Histone 12 3.37E-14
PF00617 RasGEF 11 9.15E-12
PF00618 RasGEF_N 11 5.99E-11
PF05192 MutS_III 11 6.15E-10
PF00621 RhoGEF 10 6.40E-10
PF00515 TPR_1 10 6.73E-06
PF02984 Cyclin_C 10 7.19E-06
The first two columns are Pfam domain ID and name. The third column is the
number of involved domain-domain interactions of each domain within gene
signatures against the whole genome and then compared it to that expected
by chance using Z-test (P-value in the fourth column).
doi:10.1371/journal.pcbi.1001114.t001
Figure 5. Predictive performance comparison between differ-
ent approaches. (A) Our approach was applied on the same data set
as Taylor et al [12]. Compared to the predictive performance of Taylor
et al, our approach achieved better accuracy of 83.2% (with somatic
mutation data) and 81.7% (without somatic mutation data). (B) Our
approach was applied on the same data set as Chuang et al [14], Wang
et al [10] and van de Vijver et al [25] and achieved better accuracy of
83.2% (with somatic mutation data) and 81.7% (without somatic
mutation data) compared to other three approaches (Chuang et al with
accuracy of 72.2%, Wang et al with accuracy of 62% and van de Vijver
et al with accuracy of 63%).
doi:10.1371/journal.pcbi.1001114.g005
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expression profiles of 34 patients without disease recurrence and
76 patients with disease recurrence [48]. We applied our
approach to this data set using the five-fold cross-validation
strategy. We observed that our approach achieved the accuracy
of 90.1%, the sensitivity of 90.4% and the specificity of 88.6%,
further validating the robustness of our predictive approach when
tested on different types of cancer data sets. The good predictive
performance is also demonstrated by the 10-year survival curve
(Mantel-Cox Log Rank test, nominal P-value=3.12610
212)
(Figure 6C).
Discussion
Biological network information has been proven to be a useful
feature to improve prognosis performance [12,14]. In this
context, our study constitutes the first predictive method to
classify cancer outcomes based on the information of protein
interaction interfaces in the protein interaction networks.
Compared to previous predictive approaches, the most outstand-
ing feature of CAERUS is that we investigated biological network
disruptions linked to cancer outcomes at the protein domain
level. The favorable predictive performance of our approach
suggests that association exists between cancer outcome and the
alteration in the protein interaction network, and more
importantly, that the alteration is probably caused by the genetic
variations within interacting domains. These genetic variations
are capable of interrupting the physical interactions between
proteins and thus causing abnormal biological functions associ-
ated with cancer progression. In this study, we applied CAERUS
primarily on breast cancer data sets and achieved favorable
predictive performance. However, the strength of CAERUS is
not restricted to a certain type of cancer; other types of cancer
such as ovarian cancer can be analyzed in a similar manner. It is
worth noting that the potential of the approach described in this
study is restrained by the limitations of currently available data
sources, as these data sources, such as the protein interaction
data, the domain interaction data, the gene expression data are
incomplete and also contain biases. The currently available
somatic mutation data is also limited and not individual-based.
With the growth in the size and better quality of these data sets,
our study would lead to a more reliable and robust prognosis tool
to access cancer outcome. Furthermore, this study could be
optimized with the integration of additional types of data. For
instance, we could achieve better predictive performance by
integrating the patients’ transcriptome data obtained via the
RNA-seq technology which measures gene expression levels more
accurately compared to the microarray approach [49]. With
patient-specific somatic data, it will become possible to fine-tune
the CAERUS approach and we would be able to achieve better
performance. In addition, the effects of protein post-translation
modifications such as phosphorylation, methylation and acetyla-
tion could also be potentially integrated into our model to reflect
the influence of these types of modifications on the organization
of the protein-protein interaction network during cancer
development. In conclusion, we presented a novel and integrated
approach to predict different cancer outcomes, which could be of
significant clinical application.
Materials and Methods
Data set collection
We downloaded 108,307 unique PPIs in human from the
iRefIndex database (ftp://ftp.no.embnet.org/irefindex/data) ver-
sion of June 4, 2009. The iRefIndex database [50] provides a non-
Figure 6. The ability of our approach to predict survival between two groups of breast cancer patients using different independent
data sets. (A) The Kaplan-Meier survival plot for disease-free survival is shown for good or poor prognostic groups derived from an independent
breast cancer date set from Miller et al. [46]. The difference between two groups is statistically significant for 10-year survival at the P-value of
1.8610
225 by the Mantel-Cox Log Rank test. (B) The Kaplan-Meier survival plot for disease-free survival is shown for good or poor prognostic groups
derived from another breast cancer independent date set from Chin et al. [47]. The difference between two groups is statistically significant for 10-
year survival at the P-value of 7610
24 by the Mantel-Cox Log Rank test. (C) The Kaplan-Meier survival plot for disease-free survival is shown for good
or poor prognostic groups derived from an ovarian cancer data set from Yoshihara et al. [48]. The difference between two groups is statistically
significant for 10-year survival at the P-value of 3.12610
212 by the Mantel-Cox Log Rank test.
doi:10.1371/journal.pcbi.1001114.g006
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protein interaction databases including BIND, BioGRID,
CORUM, DIP, HPRD, IntAct, MINT, MPact, MPPI and
OPHID. We also used a set of DDIs downloaded from the iPfam
database [51], a DDI database based on RCSB Protein Data Back
(PDB) crystal structures (http://www.pdb.org), which consists of
3,020 DDIs and 914 domains. For somatic mutations involved in
cancer, a list of 88,641 somatic mutations was retrieved from the
COSMIC database (version 43) that contains the mutation data
and associated information extracted from the primary literature
[52].
A set of gene expression profiles of 295 breast cancer patients
and clinical results was collected from the work of van de Vijver
and colleagues [25]. This data set was applied to test the
performance of CAERUS. We defined patients who were
disease free after extended follow-up as patients with ‘good
outcome’ and those who died of disease as patients with ‘poor
outcome’. The data was filtered to remove patients that were
still alive with disease or dead from other reasons, as reported by
Taylor [12]. The resultant dataset contained 179 patients with
‘good outcome’ and 74 patients with ‘poor outcome’. The mean
duration of follow-up was 7.5 years for ‘good outcome’ patients
and 2.8 years for ‘poor outcome’ patients. Two independent
breast cancer data sets were employed for the validation
purpose. The first data set consists of gene expression profiles
of 236 patients with primary invasive breast tumors that derived
from oligonucleotide arrays and the corresponding survival data
of these patients were collected based on the patient records
accompanying with the paper [46]. In this data set, 134 patients
were classified as ‘good outcomes’ and 102 patients with ‘bad
outcomes’ using the same abovementioned criteria. The mean
duration of follow-up was 10.9 years for ‘good outcome’ patients
and 4.9 years for ‘poor outcome’ patients. The second data set
was obtained from the gene expression profiles of a cohort of
117 patients with breast tumors, of which 83 patients had ‘good
outcomes’ and 34 patients had ‘bad outcomes’ derived from
each patient’s survival duration and disease recurrence infor-
mation included in the paper [47]. The mean duration of
follow-up was 7.2 years for ‘good outcome’ patients and 2.1
years for ‘poor outcome’ patients. In addition, we compiled the
data from a set of 110 Japanese patients who were diagnosed
with advanced-stage serous ovarian cancers [48]. The gene
expression profiles and the clinical characteristics of each patient
were extracted from the supporting materials of the paper, in
which 34 patients were labeled as ‘good outcomes’ and 76
patients as ‘bad outcomes’ using the same criteria described in
previous data sets. The mean duration of follow-up was 3.3
years for ‘good outcome’ patients and 1.2 years for ‘poor
outcome’ patients.
Gene signature finding algorithm
Step A. We have a query network X comprised of proteins
{x1,… ,x n} and known PPIs between xi and xj from the iRefIndex
database. For each protein xi in the query PPI network, we have a
mapping function D(xi)={d 1,… ,d n} that returns the set of
annotated domains of this protein according to the Pfam database.
Here, di are the individual domains.
Step B. For each domain di in the domain set D(xi), we
counted the number of domain pairs on aggregate between di and
a set of domains of neighboring/interacting proteins neighbor[xi]
represented in the interacting domain-domain pairs previously
established in the iPfam database.
Step C. A domain index score was assigned to each protein in
the query PPI network by the following equation:
Sxi~
P jD(xi)j
n~1
WNumDDIs(di)
jD(xi)j ifjD(xi)j=0,
0 otherwise:
8
> > <
> > :
9
> > =
> > ;
where NumDDIs(di) is the number of DDIs of between di and a set
of domains of neighboring/interacting proteins as calculated by
the Step B. Here, W is an exponential function at the base of 2,
which meant that we add weights exponentially to a domain if it
has multiple DDIs. In order to take it into account that somatic
mutations occur within domains, we used to a modified domain
index function to calculate scores to each protein:
Sxi~
P jD(xi)j
n~1
NumSMs(di)|WNumDDIs(di)
jD(xi)j ifjD(xi)j=0,
0 otherwise:
8
> > <
> > :
9
> > =
> > ;
where NumSMs(di) is the number of somatic mutations of di.
Step D. For each protein xi, if the domain index score was
over the preset threshold c, this protein was regarded as a gene
signature and was utilized for the neighboring gene expression
analysis. The threshold c was tuned by performing a modified five-
fold cross-validation strategy in which we firstly adopted the leave-
one-out cross-validation (LOOCV) strategy for different Sxi using
80% of the original data set (expression profiles), and then used the
discovered value c to validate against the remaining data set (20%).
This procedure was repeated 5 times in a manner that each data
point (a gene expression profile) in the dataset was used once as the
validation data.
Calculation of neighboring gene expression profiling
score
Given a gene expression data set and a gene signature x,w e
computed a score to measure the difference in co-expression of the
gene signature and its neighboring proteins P={p1, …., pn) in the
PPI network between two types of cancer outcomes (‘‘good/
disease-free’’ vs. ‘‘poor/recurrent disease’’) using the following
equation:
sx,Pdiff ~
P n
i~1
rx,pi,good{rx,pi,poor
n{1
where n is the number of interactors of the gene signature x; rx,pi,good
and rx,pi,poor is the Pearson correlation coefficient of expression
values of protein x and its interactors P={p1, …., pn} in different
groups of patients (good or poor). The Pearson correlation
coefficient of expression values of protein x and its interactors in
the different groups is calculated by the following equation:
rx,pi,group~
P
(Ex,group{Ex,group)(Epi,group{Epi,group)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
(Ex,group{Ex,group)
2
q ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
(Epi,group{Epi,group)
2
q
Construction of the naı ¨ve Bayes classifier
As a probabilistic model based on the Bayes’ theorem, the naı ¨ve
Bayes classifier has been widely applied to the classification
problem in different fields of the biological sciences such as
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pathways [54] and the prediction of protein-protein interaction
interfaces [55]. Given the training dataset and testing dataset in
which each data sample is represented as an n-dimensional vector
(dx1, dx2 …, dxn), 2 classes (Cgood,C poor). Here, n is the number of
gene signatures; dxi is the difference in co-expression of the gene
signature i and its neighboring proteins in the PPI network in
patient x. The prediction procedure follows as:
According to the Bayes theorem, we can get the highest
posterior probability of each cancer patient sample x based on the
following equation:
P(Cgoodjx)~
( P
n
i~1
P(dxijCgood))P(Cgood)
P(x)
where the class prior probabilities P(Cgood) is calculated by Xgood/
X, the value of the number of training samples of class Cgood
divided by the total number of training sample. P(dx1|Cgood),
P(dx2|Cgood), …, P(dxn|Cgood) can be easily calculated by
Xgood xi ðÞ
.
Xgood, where Xgood xi ðÞis the number of training
samples of class Cgood having the gene expression difference score
dxi falling into one certain bin/category, and Xgood the number of
training samples belonging to Cgood. In this study, we divided the
gene expression difference score into 20 bins as it ranges from 0 to
1.
In order to classify cancer patient samples in the testing dataset,
we calculated the P(x|Ci)P(Ci) for each class Ci. Sample/patient x
was then predicted as belonging to class Cgood if and only if
P(xjCgood)P(Cgood)wP(xjCpoor)P(Cpoor)
In other words, it is assigned to the class Cgood for which
P(x|Cgood)P(Cgood) is the maximum.
Availability
The method has been implemented in Perl and is available for
downloading from http://www.oicr.on.ca/research/ouellette/
caerus. It is distributed under the terms of GPL (http://
opensource.org/licenses/gpl-2.0.php)
Supporting Information
Figure S1 The performance of our approach using 410 known
cancer susceptibility genes as gene signatures. Curve of receiver
operating characteristic (ROC) plotted for different thresholds
when our approach was tested against the breast cancer data set
incorporating somatic mutation. The area under the curve (AUC)
is 0.726.
Found at: doi:10.1371/journal.pcbi.1001114.s001 (0.44 MB TIF)
Figure S2 The distribution of the predictive performance of our
approach using different random gene signature sets. CAERUS was
tested on randomized 126 genes from the list of 171 gene signatures
and this procedure was repeated 100 times. Histogram of the area
under the curve (AUC) values was plotted for 100 runs. Red vertical
bar represents the AUC value of using 126 gene signatures
identified by incorporating the somatic mutation data set.
Found at: doi:10.1371/journal.pcbi.1001114.s002 (0.65 MB TIF)
Table S1 A list of 222 over-represented GO terms associated
with identified gene signatures.
Found at: doi:10.1371/journal.pcbi.1001114.s003 (0.09 MB XLS)
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